Pfizer Expands to Multiple Myeloma With FDA Approval for New Antibody Drug
Oncology is already a big piece of Pfizer’s drug lineup. The portfolio is expanding to multiple myeloma with FDA approval of Elrexfio, a bispecific antibody that targets the cancer protein BCMA.